Experimental weight-loss drug leads to 30% body weight loss in obese patients 

Good Morning America | Liz Neporent and Shafiq Najib. Results from a late-stage clinical trial by Eli Lilly and Company include that its experimental weight-loss drug, retatrutide, led to an average weight loss of 70.3 pounds over 80 weeks in patients with obesity. What’s more, 45% of the most obese patients taking the highest dose, a once-weekly injection of 12 milligrams, lost 30% or more of their body weight. The drug targets three hormone receptors and isn’t yet FDA-approved. The company released the latest clinical trial findings, but they haven’t been published in a peer-reviewed journal. (Read)